世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

アジア太平洋地域のがんバイオマーカー市場予測 2019-2027年

ASIA PACIFIC CANCER BIOMARKER MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2019年1月US$1,250
シングルユーザライセンス(印刷不可PDF)
74

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートはアジア太平洋地域のがんバイオマーカー市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS
The Asia-Pacific cancer biomarkers market is expected to rise with a CAGR of 13.23% for the years 2019-2027. Development in the healthcare facility in the region and growing government efforts to increase awareness are the major driving force for the market in the Asia Pacific region.

MARKET INSIGHTS

The economies studied in the APAC region include China, Japan, India, Australia, South Korea and Rest of APAC. India and China are the prime countries contributing highest in the APAC cancer biomarker market. Moreover, the adoption of western lifestyles in developing countries, prevailing high population and the growing cancer research in the Asian countries are also accelerating the growth of the market. However, the low estimated rate for successful clinical trials and the various technical issues related to cancer biomarkers is expected to challenge the market growth over the forecasting period.

COMPETITIVE INSIGHTS

Some of the established companies in this market are Astellas Pharma Inc., Celgene Corporation, Diadexus Inc. (Acquired By Diazyme Laboratories), Becton Dickinson and Company, Abbott Laboratories, Bristol-Myers Squibb, Sanofi, Clarient, Inc. (Acquired By Neogenomics Laboratories), Aureon Biosciences, Inc., Illumina, Inc., Roche Diagnostics Ltd., Agilent Technologies, Inc., Qiagen N.V., Agendia N.V. and Beckman Coulter.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
3.2.2. GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
3.2.3. BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
3.2.4. DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. ADOPTION OF WESTERN LIFESTYLES IN DEVELOPING REGIONS
4.2.2. GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
4.2.3. IMPROVED PRECISION AND SPEED OF DIAGNOSIS
4.2.4. HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
4.2.5. DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
4.2.6. GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
4.2.7. TECHNOLOGICAL ADVANCEMENTS
4.2.8. GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
4.3. MARKET RESTRAINTS
4.3.1. POOR COMPENSATION STRUCTURES
4.3.2. LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
4.3.3. TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
4.3.4. HIGH COST OF DRUG DEVELOPMENT
4.3.5. UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
4.4. MARKET OPPORTUNITIES
4.4.1. WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
4.4.2. SUPPORT ON BIOMARKERS TEST
4.4.3. GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
4.4.4. ADVANCEMENT OF CANCER DRUGS RESEARCH
4.5. MARKET CHALLENGES
4.5.1. LACKING ACCEPTANCE OF THE CANCER BIOMARKER
4.5.2. UNFAVORABLE COMPENSATION SITUATION
4.5.3. HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
4.5.4. RIGOROUS REGULATORY AGENDA
4.5.5. DEARTH OF SKILFUL WORKERS
5. MARKET BY PROFILING TECHNOLOGY
5.1. OMIC TECHNOLOGY
5.2. IMAGING TECHNOLOGIES
5.3. IMMUNOASSAYS
5.4. CYTOGENETIC-BASED TESTS
6. MARKET BY BIOMARKER
6.1. GENETIC BIOMARKERS
6.2. PROTEIN BIOMARKERS
6.3. GLYCO BIOMARKERS
7. MARKET BY CANCER TYPE
7.1. LUNG CANCER
7.2. BREAST CANCER
7.3. COLORECTAL CANCER
7.4. PROSTATE CANCER
7.5. STOMACH CANCER
7.6. OTHERS CANCER TYPE
8. MARKET BY APPLICATION
8.1. DIAGNOSTICS
8.2. DRUG DISCOVERY AND DEVELOPMENT
8.3. PROGNOSTICS
8.4. RISK ASSESSMENT
8.5. OTHER APPLICATION
9. KEY ANALYTICS
9.1. PORTER’S FIVE FORCE ANALYSIS
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCT
9.1.3. BARGAINING POWER OF BUYER
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. KEY BUYING CRITERIA
9.2.1. PRICING
9.2.2. EFFICACY
9.2.3. APPLICATION AND EFFECTIVENESS
9.3. PATENT ANALYSIS
9.4. OPPORTUNITY MATRIX
10. GEOGRAPHICAL ANALYSIS
10.1. ASIA PACIFIC
10.1.1. CHINA
10.1.2. INDIA
10.1.3. JAPAN
10.1.4. SOUTH KOREA
10.1.5. AUSTRALIA
10.1.6. REST OF APAC
11. COMPETITIVE LANDSCAPE
11.1. MARKET SHARE ANALYSIS
11.2. COMPANY PROFILES
11.2.1. ABBOTT LABORATORIES
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.1.3. SCOT ANALYSIS
11.2.1.4. STRATEGIC INITIATIVES
11.2.2. AGENDIA N.V.
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. SCOT ANALYSIS
11.2.2.4. STRATEGIC INITIATIVES
11.2.3. AGILENT TECHNOLOGIES, INC.
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. SCOT ANALYSIS
11.2.3.4. STRATEGIC INITIATIVES
11.2.4. AUREON BIOSCIENCES, INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. SCOT ANALYSIS
11.2.4.4. STRATEGIC INITIATIVES
11.2.5. ASTELLAS PHARMA INC.
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.5.3. SCOT ANALYSIS
11.2.5.4. STRATEGIC INITIATIVES
11.2.6. BECKMAN COULTER
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.6.3. SCOT ANALYSIS
11.2.6.4. STRATEGIC INITIATIVES
11.2.7. BECTON DICKINSON AND COMPANY
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. SCOT ANALYSIS
11.2.7.4. STRATEGIC INITIATIVES
11.2.8. BRISTOL-MYERS SQUIBB
11.2.8.1. COMPANY PROFILES
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. SCOT ANALYSIS
11.2.8.4. STRATEGIC INITIATIVES
11.2.9. CELGENE CORPORATION
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.9.3. SCOT ANALYSIS
11.2.9.4. STRATEGIC INITIATIVES
11.2.10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.10.3. SCOT ANALYSIS
11.2.10.4. STRATEGIC INITIATIVES
11.2.11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. SCOT ANALYSIS
11.2.11.4. STRATEGIC INITIATIVES
11.2.12. ILLUMINA, INC.
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.12.3. SCOT ANALYSIS
11.2.12.4. STRATEGIC INITIATIVES
11.2.13. ROCHE DIAGNOSTICS LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.13.3. SCOT ANALYSIS
11.2.13.4. STRATEGIC INITIATIVES
11.2.14. SANOFI
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS PORTFOLIO
11.2.14.3. SCOT ANALYSIS
11.2.14.4. STRATEGIC INITIATIVES
11.2.15. QIAGEN N.V.
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. SCOT ANALYSIS
11.2.15.4. STRATEGIC INITIATIVES

TABLE LIST
TABLE 1 ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 4 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 5 ASIA PACIFIC CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 6 ASIA PACIFIC OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 7 ASIA PACIFIC IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)
TABLE 8 ASIA PACIFIC IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)
TABLE 9 ASIA PACIFIC CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)
TABLE 10 ASIA PACIFIC CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 11 ASIA PACIFIC GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 12 ASIA PACIFIC PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 13 ASIA PACIFIC GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 14 ASIA PACIFIC CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 15 ASIA PACIFIC LUNG CANCER MARKET 2019-2027 ($ MILLION)
TABLE 16 ASIA PACIFIC BREAST CANCER MARKET 2019-2027 ($ MILLION)
TABLE 17 ASIA PACIFIC COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)
TABLE 18 ASIA PACIFIC PROSTATE CANCER MARKET 2019-2027 ($ MILLION)
TABLE 19 ASIA PACIFIC STOMACH CANCER MARKET 2019-2027 ($ MILLION)
TABLE 20 ASIA PACIFIC OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)
TABLE 21 ASIA PACIFIC CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 22 ASIA PACIFIC DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 23 ASIA PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)
TABLE 24 ASIA PACIFIC PROGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 25 ASIA PACIFIC RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)
TABLE 26 ASIA PACIFIC OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 27 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 28 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 29 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 30 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 31 ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 32 STATE-WISE DISTRIBUTION OF CANCER IN INDIA
TABLE 33 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017


FIGURES LIST
FIGURE 1 ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 4 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 5 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 6 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 7 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 8 PORTER’S FIVE FORCE ANALYSIS
FIGURE 9 ASIA PACIFIC CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 10 CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 11 INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 12 JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 13 SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 14 AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 15 REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 16 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

List of Tables

TABLE LIST
TABLE 1 ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 4 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 5 ASIA PACIFIC CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 6 ASIA PACIFIC OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 7 ASIA PACIFIC IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)
TABLE 8 ASIA PACIFIC IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)
TABLE 9 ASIA PACIFIC CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)
TABLE 10 ASIA PACIFIC CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 11 ASIA PACIFIC GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 12 ASIA PACIFIC PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 13 ASIA PACIFIC GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 14 ASIA PACIFIC CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 15 ASIA PACIFIC LUNG CANCER MARKET 2019-2027 ($ MILLION)
TABLE 16 ASIA PACIFIC BREAST CANCER MARKET 2019-2027 ($ MILLION)
TABLE 17 ASIA PACIFIC COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)
TABLE 18 ASIA PACIFIC PROSTATE CANCER MARKET 2019-2027 ($ MILLION)
TABLE 19 ASIA PACIFIC STOMACH CANCER MARKET 2019-2027 ($ MILLION)
TABLE 20 ASIA PACIFIC OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)
TABLE 21 ASIA PACIFIC CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 22 ASIA PACIFIC DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 23 ASIA PACIFIC DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)
TABLE 24 ASIA PACIFIC PROGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 25 ASIA PACIFIC RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)
TABLE 26 ASIA PACIFIC OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 27 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 28 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 29 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 30 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 31 ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 32 STATE-WISE DISTRIBUTION OF CANCER IN INDIA
TABLE 33 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017

List of Figures

FIGURES LIST
FIGURE 1 ASIA PACIFIC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 4 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 5 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 6 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 7 ASIA PACIFIC CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 8 PORTER’S FIVE FORCE ANALYSIS
FIGURE 9 ASIA PACIFIC CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 10 CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 11 INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 12 JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 13 SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 14 AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 15 REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 16 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る